A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 8, 2014, Pages 1544-1552

  Servagi Vernat, Stéphanie ^a,b   Differding, Sarah ^a   Hanin, Francois Xavier ^a   Labar, Daniel ^a   Bol, Anne ^a   Lee, John A ^a   Grégoire, Vincent ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Head and neck squamous cell carcinoma; Hypoxia imaging; Positron emission tomography (PET); Radiotherapy

Indexed keywords

18F FLUOROAZOMYCIN ARABINOSIDE; CARBOPLATIN; CETUXIMAB; FLUOROURACIL; TRACER; UNCLASSIFIED DRUG; FLUOROAZOMYCIN ARABINOSIDE; NITROIMIDAZOLE DERIVATIVE; OXYGEN; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; FEMALE; GEOGRAPHIC DISTRIBUTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXEMIA; INTENSITY MODULATED RADIATION THERAPY; LARYNX SQUAMOUS CELL CARCINOMA; LOADING DRUG DOSE; MALE; NECK MUSCLE; OROPHARYNX CARCINOMA; PET-CT SCANNER; PRIMARY TUMOR; PROSPECTIVE STUDY; PYRIFORM SINUS; RADIATION DOSE ESCALATION; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; DIAGNOSTIC USE; EVALUATION STUDY; HEAD AND NECK NEOPLASMS; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

AGED; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS;

EID: 84905586483     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2730-x     Document Type: Article

References (50)

1. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28(2 Suppl 8):29-35. (Pubitemid 32522235)
2. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 2006;24(5):727-35. (Pubitemid 46622039)
3. NordsmarkM, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol. 2005;77(1):18-24. (Pubitemid 41503384)
4. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48(2):149-56. (Pubitemid 28423786)
5. Lee DJ, Pajak TF, Stetz J, Order SE, Weissberg JB, Fischer JJ. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). Int J Radiat Oncol, Biol, Phys. 1989;16(2):465-70. (Pubitemid 19077212)
6. Villar A, Martinez JC, de Serdio JL. Chemoradiation for advanced head and neck cancer: potential for improving results to match those of current treatment modalities for early-stage tumors - long-term results of hyperfractionated chemoradiation with carbogen breathing and anemia correction with erythropoietin. Int J Radiat Oncol, Biol, Phys. 2008;70(5):1382-8. (Pubitemid 351417763)
7. Overgaard J, Horsman MR. Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. Semin Radiat Oncol. 1996;6(1):10-21. (Pubitemid 26029371)
8. Mizoe JE, Hasegawa A, Jingu K, Takagi R, Bessyo H, Morikawa T, et al. Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol. 2012;103(1):32-7.
9. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012;30(15):1777-83.
10. Toustrup K, Sorensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol. 2012;22(2):119-27.
11. Mueller-Klieser W, Schlenger KH, Walenta S, Gross M, Karbach U, HoeckelM, et al. Pathophysiological approaches to identifying tumor hypoxia in patients. Radiother Oncol. 1991;20 Suppl 1:21-8.
12. Busk M, Horsman MR, Jakobsen S, Keiding S, van der Kogel AJ, Bussink J, et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol, Biol, Phys. 2008;70(4):1202-12. (Pubitemid 351296127)
13. Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging. 2006;33 Suppl 1:44-53.
14. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225-39. (Pubitemid 47101660)
15. Lapi SE, Voller TF, Welch MJ. Positron Emission Tomography Imaging of Hypoxia. PET Clin. 2009;4(1):39-47.
16. Lehtio K, Oikonen V, Nyman S, Gronroos T, Roivainen A, Eskola O, et al. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18 F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging. 2003;30(1):101-8.
17. Mahy P, De Bast M, de Groot T, Cheguillaume A, Gillart J, Haustermans K, et al. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18 F]-EF3 and [18 F]-MISO in rodent tumor models. Radiother Oncol. 2008;89(3):353-60.
18. Mahy P, De Bast M, Gillart J, Labar D, Gregoire V. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging. 2006;33(5):553-6.
19. Mahy P, De Bast M, Leveque PH, Gillart J, Labar D, Marchand J, et al. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3. Eur J Nucl Med Mol Imaging. 2004;31(9):1263-72. (Pubitemid 39222490)
20. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18 F-fluoroazomycin arabinoside. J Nucl Med. 2005;46(1):106-13. (Pubitemid 43086004)
21. Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos TJ, Forsback S, et al. 18 F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med. 2008;49(12):1944-51.
22. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. (1)(8)FHX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with (1)(8)F-FMISO. Nucl Med Commun. 2012;33(10):1096-102.
23. Wijsman R, Kaanders JH, Oyen WJ, Bussink J. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography. Q J Nucl Med Mol Imaging. 2013;57(3):244-56.
24. Clausen MM, Hansen AE, Af Rosenschold PM, Kjaer A, Kristensen AT, McEvoy FJ, et al. Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiat Oncol. 2013;8:262.
25. Geets X, Gregoire V, Lee JA. Implementation of hypoxia PET imaging in radiation therapy planning. Q J Nucl Med Mol Imaging. 2013;57(3):271-82.
26. Bentzen SM, Gregoire V. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol. 2011;21(2):101-10.
27. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91(24):2081-6. (Pubitemid 30019568)
28. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-78. (Pubitemid 43209104)
29. EudraLex TRGMPitEU. Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Volume 4; Annex 3 Manufacture of Radiopharmaceuticals.
30. Reischl G, Ehrlichmann W, Bieg C, Solbach C, Kumar P, Wiebe LI, et al. Preparation of the hypoxia imaging PET tracer [18 F]FAZA: reaction parameters and automation. Appl Radiat Isot. 2005;62(6):897-901. (Pubitemid 40432058)
31. SouvatzoglouM, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18 F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34(10):1566-75. (Pubitemid 47476913)
32. Trinkaus ME, Blum R, Rischin D, Callahan J, Bressel M, Segard T, et al. Imaging of hypoxia with 18 F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. J Med Imaging Radiat Oncol. 2013;57(4):475-81.
33. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging. 2013;40(2):186-97.
34. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105(1):14-20.
35. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol, Biol, Phys. 2007;69(2):541-51. (Pubitemid 47380112)
36. Mahy P, De BastM, Gallez B, Gueulette J, Koch CJ, Scalliet P, et al. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. Radiother Oncol. 2003;67(1):53-61. (Pubitemid 36570440)
37. Tran LB, Bol A, Labar D, Jordan B, Magat J, Mignion L, et al. Hypoxia imaging with the nitroimidazole 18 F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. Radiother Oncol. 2012;105(1):29-35.
38. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18 F] fluoromisonidazole and [18 F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer. 2007;7:113.
39. Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P, et al. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol. 2004;180(10):616-22. (Pubitemid 39361958)
40. Bartlett RM, Beattie BJ, NaryananM, Georgi JC, Chen Q, Carlin SD, et al. Image-guided PO2 probe measurements correlated with parametric images derived from 18 F-fluoromisonidazole small-animal PET data in rats. J Nucl Med. 2012;53(10):1608-15.
41. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, et al. FDG-a marker of tumour hypoxia? A comparison with [18 F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging. 2006;33(12):1426-31. (Pubitemid 44885408)
42. NordsmarkM, OvergaardM, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41(1):31-9. (Pubitemid 26396294)
43. Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M. Kinetic analysis of dynamic 18 F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer. 2005;5:152.
44. Rischin D, Fisher R, Peters L, Corry J, Hicks R. Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. Int J Radiat Oncol, Biol, Phys. 2007;69(2 Suppl):S61-3. (Pubitemid 47369395)
45. Duprez F, De NeveW, De GersemW, CogheM, Madani I. Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol, Biol, Phys. 2011;80(4):1045-55.
46. Madani I, Duprez F, Boterberg T, Van deWiele C, Bonte K, Deron P, et al. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiother Oncol. 2011;101(3):351-5.
47. Madani I, Duthoy W, Derie C, De Gersem W, Boterberg T, Saerens M, et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol, Biol, Phys. 2007;68(1):126-35. (Pubitemid 46589860)
48. Malinen E, Sovik A, Hristov D, Bruland OS, Olsen DR. Adapting radiotherapy to hypoxic tumours. Phys Med Biol. 2006;51(19):4903-21. (Pubitemid 44429851)
49. Sovik A, Malinen E, Skogmo HK, Bentzen SM, Bruland OS, Olsen DR. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol, Biol, Phys. 2007;68(5):1496-504. (Pubitemid 47179905)
50. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J RadiatOncol, Biol, Phys. 2007;68(1):291-300. (Pubitemid 46589864)